Market Intel: Opportunities for Medtech In Mental Health (Part 1) – Transcranial Magnetic Stimulation
Executive Summary
With the global pandemic leading to a big rise in mental health issues, medtech could have a role to play. In this first part of a two-part series focusing on mental health tech, Medtech Insight focuses on transcranial magnetic stimulation systems used to treat severe anxiety and depression, among other indications. Part two will focus on the skyrocketing use of telehealth, apps and light therapy.
You may also be interested in...
Execs On The Move: Management, Marketing Changes At Medtronic And Brainsway; New CEO At Tactile Medical
A new CMO and VP is selected at Medtronic’s Coronary and Structural Heart division; Brainsway, a developer of neuromodulation products, decides on a VP for global marketing; Tactile Medical, offering treatments for lymphedema and venous ulcers; announced a new CEO; and more.
OCD Indication Approved For Brainsway TMS Device
US FDA used its de novo review pathway to approve Brainsway Ltd.’s Brainsway Deep Transcranial Magnetic Stimulation System to treat obsessive compulsive disorder.
Happify Health Collaborates With Biogen To Support People Living With Multiple Sclerosis
Biogen and Happy Health announced a pilot partnership to evaluate Happify Health’s Kopa app to support people living with multiple sclerosis. This follows a licensing deal with digital therapeutics developer MedRhythms to support MS patients with gait deficit.